This study is testing a medicine called vixarelimab to see if it helps people with lung diseases like Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD). IPF makes lungs stiff and hard to breathe, while SSc-ILD involves thickening and scarring in the lungs. The study compares vixarelimab to a placebo (a "fake" treatment) to see if it improves lung function.

Participants take part for 52 weeks and can choose to continue for another 52 weeks with the real medicine. The study is split into two groups: one for people with IPF and the other for those with SSc-ILD. It is important to know that the first group is full, but the second group is still accepting participants.

• The study lasts for 1 to 2 years, depending on participation in the optional extension period.
• Participants may receive treatment with vixarelimab for the second year.
• Potential risks include respiratory infections and other side effects related to lung diseases.